How different are luminal A and basal breast cancers?

Area of Science:

• Oncology
• Molecular Biology
• Genomics

Background:

• Breast cancer exhibits significant heterogeneity, with at least five molecular subtypes.
• Luminal A and basal subtypes represent major classifications with opposing clinical outcomes.
• Optimal treatment strategies are hindered by the complex evolution and prediction of breast cancer subtypes.

Purpose of the Study:

• To comprehensively characterize the molecular differences between luminal A and basal breast cancer subtypes.
• To identify distinct biological pathways and gene expression patterns specific to each subtype.
• To uncover potential diagnostic, prognostic, and therapeutic targets for improved patient management.

Main Methods:

• Whole-genome DNA microarray profiling of 138 breast tumors (80 luminal A, 58 basal).
• Identification and validation of differentially expressed probe sets across 6 independent public datasets (>600 tumors).
• Functional and pathway analysis of identified differentially expressed genes.

Main Results:

• Identified 5,621 differentially expressed probe sets between luminal A and basal subtypes.
• Basal tumors overexpressed genes related to proliferation, cell cycle, motility, angiogenesis, and NFkB signaling.
• Luminal A tumors overexpressed genes involved in fatty acid metabolism, TGFB, and estrogen receptor (ER) signaling, with many containing ER-binding sites.

Conclusions:

• Luminal A and basal breast cancer subtypes are distinct molecular entities with unique biological characteristics.
• The identified gene expression signatures provide a basis for subtype-specific diagnostic and prognostic markers.
• Profound molecular differences necessitate tailored therapeutic strategies for luminal A and basal breast cancers.